ECSS
RVMD icon

Eurizon Capital SGR SpA’s Revolution Medicines RVMD Stock Holding History

Eurizon Capital SGR SpA’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
8,985
+5,537
+161% +$809K ﹤0.01% 558
2026
Q1 		$328K Buy
3,448
+1,200
+53% +$121K ﹤0.01% 692
2025
Q4 		$179K Buy
+2,248
New +$147K ﹤0.01% 663

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Eurizon Capital SGR SpA's RVMD Position: Q2 2026 in Review

Eurizon Capital SGR SpA increased its Revolution Medicines (RVMD) stake by 161% in Q2 2026, buying an estimated $809K and bringing the position to 8,985 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Eurizon Capital SGR SpA first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Eurizon Capital SGR SpA held 8,985 shares of Revolution Medicines worth $1.69M as of Q2 2026.
  • Eurizon Capital SGR SpA bought 5,537 Revolution Medicines shares in Q2 2026, an estimated $809K.
  • Revolution Medicines made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #558 holding.
  • Eurizon Capital SGR SpA first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.